The number most often cited to describe the scale of nonmelanoma skin cancer in the United States is 14 years out of date, and a new analysis from SkinCure Oncology suggests the true annual patient count is 4.7 million, not the 3.3 million figure drawn from 2012 data and published in a 2015 study. That gap, roughly 42 percent, translates to more than a million patients who fall outside the count that policymakers and insurers have been using to size the problem.
Four separate methodologies in the analysis converge on the same conservative floor. The most straightforward: NMSC concentrates heavily in adults 60 and older, accounting for about 80 percent of cases, and the U.S. population aged 65 and older grew by nearly 50 percent between 2012 and 2026, from 43.1 million to roughly 64 million. Holding individual risk constant at 2012 levels and adjusting only for that demographic shift produces the 4.7 million figure. A compound-growth calculation using one-third of the 2006-2012 annual growth rate arrives at the same number, and federal Medical Expenditure Panel Survey data had already placed the count above 4 million more than a decade ago. The true upper bound, based on extrapolating the actual 2006-2012 trajectory, sits closer to 5.9 million, which means 4.7 million is the floor, not a midpoint estimate.
The policy consequence SkinCure’s CEO Kerwin Brandt draws from this is a push for mandatory national reporting. Unlike most cancers, nonmelanoma skin cancers are not routinely captured by national registries in the United States, partly because their volume makes comprehensive tracking expensive. That exclusion is precisely what allowed a decade-old benchmark to persist unchallenged. Brandt is also calling for reimbursement structures that encourage early treatment across all recognized modalities, including Image-Guided Superficial Radiation Therapy, the FDA-cleared nonsurgical approach SkinCure promotes through its network of roughly 500 physicians.
SkinCure has an obvious commercial interest in a higher patient count, and the analysis comes from the company rather than an independent research group, so the 4.7 million figure warrants external validation. Still, the demographic arithmetic is straightforward, and if registry advocates use it to press for mandatory NMSC reporting, the more telling outcome will be whether CMS reimbursement policy for early-stage treatment follows the revised incidence data.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
